Wet Macular Degeneration Clinical Trial
Official title:
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
The aim of the TITAN study is to describe the clinical practices of a cohort of patients with
wAMD refractory to ranibizumab (persistence of intra-retinal and/or subretinal fluid) who
switch to aflibercept after less than 12 months of ranibizumab treatment.
The study will be conducted in real-life conditions and will allow describing conditions of
use of aflibercept in patients refractory to ranibizumab
The study is both retrsopective and prospective to collect local real life data on patients
under routine treatment.
The observation periods starts on January 2014. Patients who initiated a treatment by
Aflibercept between the 1st of january 2014 and the 31 December 2015 will be enrolled.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04049266 -
A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
| Terminated |
NCT05038371 -
Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration
|
||
| Completed |
NCT03278262 -
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
|
||
| Completed |
NCT04982484 -
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
|
||
| Completed |
NCT00590694 -
Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments
|
Phase 2/Phase 3 | |
| Completed |
NCT04516278 -
A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
| Completed |
NCT03844074 -
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 3 | |
| Recruiting |
NCT05637255 -
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT04756310 -
Study of Nutritional Supplementation in Patients With Unilateral Wet AMD
|
N/A | |
| Active, not recruiting |
NCT05112861 -
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
|
Phase 3 | |
| Enrolling by invitation |
NCT03999801 -
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
|
Phase 2 | |
| Terminated |
NCT03699618 -
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
|
||
| Completed |
NCT01666821 -
A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
|
N/A | |
| Completed |
NCT03022292 -
The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy
|
Phase 4 | |
| Completed |
NCT02944227 -
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
|
Phase 4 | |
| Terminated |
NCT03452527 -
Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
|
Phase 2 | |
| Completed |
NCT01243086 -
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
|
Phase 2 | |
| Completed |
NCT03823300 -
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
|
Phase 3 | |
| Recruiting |
NCT04420923 -
Optimizing the Treatment Strategy for Age-related Macular Degeneration
|
N/A |